Skip to main content
Clinical and Translational Medicine
Fig. 3 | Clinical and Translational Medicine

Fig. 3

From: The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

Fig. 3

Trastuzumab down-regulates ERBB2 in iPSC-derived cardiomyocytes, but not in ERBB2 overexpressing cancer cell lines. a Western blot of 15 µg of total cell lysate stained for ERBB2 in MDA-MB-231 (non-ERBB2 overexpressing breast cancer cell line negative control), and iPSC-cardiomyocytes treated with trastuzumab and lapatinib. ERBB2 expression was down-regulated by trastuzumab but not by lapatinib. b ERBB2 expression was not altered by trastuzumab in the ERBB2 overexpressing cancer cell lines, BT474 and SKBR3

Back to article page